

18 November 2020

December 2020 Section H of the Pharmaceutical Schedule – Update

The Section H Update summary is provided to DHB hospital pharmacists as a preview of the changes that will be announced in the next Update to Section H of the Pharmaceutical Schedule, and take effect from the beginning of next month.

For any questions about these listing changes, or the Pharmaceutical Schedule in general, please contact us at enquiry@pharmac.govt.nz.

Pharmaceutical	Change
Adalimumab inj 20 mg per 0.4 ml and 40 mg per 0.8 ml syringe (Humira) and inj 40 mg per 0.8 ml pen (HumiraPen)	amended restriction criteria
Amino acid formula (without phenylalanine) (e.g. PKU Anamix Infant) powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	new listing
Amino acid formula (without phenylalanine) (e.g. PKU Anamix Infant) powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	to be delisted 1 June 2021
Bupropion hydrochloride (Zyban) tab modified-release 150 mg	addition of HSS
Calcium carbonate tab 1.25 g (500 mg elemental)	Brand change <ul style="list-style-type: none"> • Calci-Tab 500 – new listing and addition of HSS (p'code 2212269) • Arrow-Calcium to be delisted 1 May 2021
Cyclizine lactate inj 50 mg per ml, 1 ml ampoule	Brand change <ul style="list-style-type: none"> • Hameln – new listing and addition of HSS (p'code 2595877) • Nausicalm to be delisted 1 May 2021
Docetaxel (DBL Docetaxel) inj 10 mg per ml, 2 ml vial	to be delisted 1 June 2021

Pharmaceutical	Change
Dornase alfa (Pulmozyme) nebuliser soln 2.5 mg per 2.5 ml ampoule	amended restriction criteria
Emicizumab (Hemlibra) inj 30 mg in 1 ml vial, 60 mg in 0.4 ml vial, 105 mg in 0.7 ml vial and 150 mg in 1 ml vial	new listing <ul style="list-style-type: none"> • Inj 30 mg in 1 ml vial (p'code 2553511) • Inj 60 mg in 0.4 ml vial (p'code 2553546) • Inj 105 mg in 0.7 ml vial (p'code 2553554) • Inj 150 mg in 1 ml vial (p'code 2553538)
Etanercept (Enbrel) inj 25 mg vial, and inj 50 mg autoinjector and syringe	amended restriction criteria
Extensively hydrolysed formula <ul style="list-style-type: none"> • powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can (Aptamil AllerPro SYNEO 1) • powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can (Aptamil AllerPro SYNEO 2) 	amended brand name
Goserelin implant 3.6 mg and 10.8 mg, syringe	Brand change Teva – new listing and addition of HSS <ul style="list-style-type: none"> • Implant 3.6 mg, syringe (p'code 2597519) • Implant 10.8 mg, syringe (p'code 2597527) Zoladex to be delisted 1 May 2021
Imatinib mesilate cap 400 mg	Brand change <ul style="list-style-type: none"> • Imatinib-Rex – new listing and addition of HSS (p'code 2594323) • Imatinib-AFT to be delisted 1 June 2021
Mitomycin C (Teva) inj 20 mg vial	new listing (p'code 2601761)
Paraldehyde soln 97%	new listing

Pharmaceutical	Change
Pegaspargase (Oncaspar LYO) inj 750 iu per ml, 5 ml vial	amended restriction criteria
Pegylated interferon alfa-2a (Pegasys) inj 180 mcg prefilled syringe	amended restriction criteria
Pimecrolimus (Elidel) crm 1%, 15 g	new listing (p'code 2098873)
Rifaximin (Xifaxan) tab 550 mg	addition of HSS
Rituximab (Mabthera) inj 10 mg per ml, 10 ml and 50 ml vial	amended restriction criteria
Tobramycin solution for inhalation 60 mg per ml, 5 ml	Brand change <ul style="list-style-type: none"> Tobramycin BNM – new listing and addition of HSS (p'code 2601648) TOBI to be delisted 1 May 2021
Tocilizumab (Actemra) inj 20 mg per ml, 4 ml, 10 ml and 20 ml vial	amended restriction criteria
Water (InterPharma) inj 5 ml and 20 ml ampoule	to be delisted 1 June 2021